Combined PKCiota and mTOR Inhibition for Treatment of Advanced Squamous Lung Cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2017
At a glance
- Drugs Sirolimus (Primary) ; Sodium aurothiomalate (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Biomarker
- 14 Dec 2012 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 18 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Jul 2011 New trial record